Ülke: Yeni Zelanda
Dil: İngilizce
Kaynak: Medsafe (Medicines Safety Authority)
Candesartan cilexetil 4mg;
Apotex NZ Ltd
Candesartan cilexetil 4 mg
4 mg
Tablet
Active: Candesartan cilexetil 4mg Excipient: Carmellose calcium Hyprolose Lactose monohydrate Magnesium stearate Maize starch Purified water Triacetin
Blister pack, PVC/PVdC/Al, 7 tablets
Prescription
Prescription
Apotex Pharmachem India Pvt. Ltd.
Treatment of hypertension.
Package - Contents - Shelf Life: Blister pack, PVC/PVdC/Al - 7 tablets - 18 months from date of manufacture stored at or below 30°C - Blister pack, PVC/PVdC/Al - 28 tablets - 18 months from date of manufacture stored at or below 30°C - Blister pack, PVC/PVdC/Al - 30 tablets - 18 months from date of manufacture stored at or below 30°C - Bottle, plastic, HDPE - 28 tablets - 18 months from date of manufacture stored at or below 30°C - Bottle, plastic, HDPE - 30 tablets - 18 months from date of manufacture stored at or below 30°C - Bottle, plastic, HDPE - 100 tablets - 18 months from date of manufacture stored at or below 30°C
2012-12-10
NEW ZEALAND DATA SHEET APO-CANDESARTAN CANDESARTAN CILEXETIL 4 MG, 8 MG, 16 MG AND 32 MG TABLETS Please refer to Medsafe website ( www.medsafe.govt.nz ) for the most recent datasheet Page 1 PRESENTATION APO-CANDESARTAN Tablets 4 mg: White to off white coloured, round shaped, biconvex tablets, engraved “APO” on one side and “CA” scored “4” on the other side. APO-CANDESARTAN Tablets 8 mg: Pink to light pink coloured, round shaped, biconvex tablets, engraved “APO” on one side and “CA” bisect “8” on the other side. APO-CANDESARTAN Tablets 16 mg: Pink to light pink coloured, round shaped, biconvex tablets, engraved “APO” on one side and “CA” bisect “16” on the other side. APO-CANDESARTAN Tablets 32 mg: Pink to light pink coloured, round shaped, biconvex tablets, engraved “APO” on one side and “CA” bisect “32” on the other side. Do not halve tablet. Dose equivalence when the tablet is divided has not been established. INDICATIONS Hypertension. Treatment of patients with heart failure and left ventricular systolic dysfunction. Treatment with APO-CANDESARTAN reduces mortality, reduces hospitalisation due to heart failure, and improves symptoms. DOSAGE AND ADMINISTRATION DOSAGE IN HYPERTENSION The recommended initial and maintenance dose of candesartan is 8 mg once daily. The dose may be increased to 16 mg once daily. In patients who require further blood pressure reduction, the dose may be increased to 32 mg once daily. Therapy should be adjusted according to blood pressure response. The maximal antihypertensive effect is attained within 4 weeks after initiation of treatment. In patients with less than optimal blood pressure reduction on candesartan combination with a thiazide diuretic is recommended. USE IN THE ELDERLY No initial dosage Belgenin tamamını okuyun